Table 2 Patient´s characteristics at the time of re-irradiation and outcomes
From: Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey
RT1-RT2 (months) | RT1-failure-RT2 (months) | Chemotherapy before RT2 | Surgery before RT2 | RT2 total Gy; dose per fraction | Site RT2 | RT2 failure | Location RT2 failure* | TTP 2 or last follow up (months) | FU after RT2 (months) | Current status | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Local relapses | |||||||||||
HypoFFRT | |||||||||||
1 | 52 | 2 | No | GTR | 35; 3.5 | 4th ventricle | No | DA | 25 | 25 | NED |
2 | 37 | 3 | No | GTR | 44; 4.4 | 4th ventricle | Yes | Metastatic | 11 | 34 | NED |
3 | 35 | 3 | No | GTR | 35; 3.5 | 4th ventricle | Yes | Infield | 31 | 31 | PD |
4 | 46 | 2 | No | GTR | 27; 4.5 | 4th ventricle | Yes | Metastatic | 15 | 57 | DOD |
5 | 16 | 4 | No | GTR | 35; 3.5 | Left parietal | Yes | Margin/mets | 5 | 12 | DOD |
6 | 22 | 3 | No | GTR | 25; 5 | Left parietal | No | DA | 37 | 37 | NED |
7 | 27 | 1 | No | NS | 14 | Left cerebellar | No | DA | 99 | 99 | NED |
8 | 34 | 1 | No | GTR | 36; 6 | 4th + Left lateral V | No | DA | 12 | 12 | NED |
FFRT | |||||||||||
9 | 44 | 33 | Yes | STR | 50.4; 1.8 | Left temporal | Yes | Infield | 19 | 27 | DOD |
10 | 70 | 9 | No | NS | 54; 1.8 | Right CP angle | Yes | Infield | 14 | 24 | NED |
11 | 31 | 18 | No | GTR | DA | Parietal | Yes | Infield | 0 | 2 | DOD |
12 | 12 | 3 | Yes | STR | 37.5; 2.5 | Fronto-parietal | Yes | Margin/mets | 3 | 19 | DOD |
13 | 23 | 5 | No | GTR | 45; 1.8 | 4th ventricle | Yes | Infield/margin | 9 | 35 | DOD |
14 | 88 | 2 | No | GTR | 59.4; 1.8 | Temporo-parietal | No | DA | 6 | 6 | NED |
15 | 38 | 2 | No | GTR | 54; 1.8 | 4th ventricle | No | DA | 69 | 69 | NED |
Metastatic relapses | |||||||||||
HypoFFRT | |||||||||||
16 | 69 | 4 | No | GTR | 51; 5.1 | Right temporal | Yes | Metastatic | 2 | 15 | DOD |
17 | 17 | 5 | No | GTR | 45; 3 | Frontal | No | DA | 17 | 17 | NED |
18 | 19 | 17 | No | GTR | 37.5; 6.25 | Left lateral ventricle | No | DA | 9 | 9 | NED |
FFRT and spinal RT | |||||||||||
19 | 51 | 6 | Yes | STR | 54; 2.25 | Suprasellar | Yes | Metastatic | 7 | 33 | DOD |
20 | 9 | 2 | No | STR | 35 + 15; 1.8 | SP(B L3-TS) | Yes | Metastatic | 8 | 22 | DOD |
21 | 12 | 2 | Yes | GTR | 54; 1.8 | Fronto-parietal | Yes | Metastatic | 2 | 35 | DOD |
22 | 8 | 3 | No | STR | 35 + 18; 1.8 | SP(B TS) | Yes | Metastatic | 15 | 42 | DOD |
23 | 15 | 1 | No | GTR | 54; 1.8 | L4-S3 | Yes | Metastatic | 11 | 18 | NED |
24 | 6 | 2 | Yes | STR | 35 + 10; 1.8 | SP(B T9-L1) | Yes | Metastatic | 6 | 9 | DOD |
25 | 10 | 2 | No | STR | 36 + 14; 1.8 | SP(B TS) | Yes | Metastatic | 13 | 25 | DOD |
CSI | |||||||||||
26 | 15 | 13 | Yes | NS | 40 + 15; 1.8 | BR (B PF) | No | DA | 140 | 140 | NED |
27 | 105 | 5 | No | GTR | 36 + 14; 1.8 | BR(PPF)/SP(B TS) | No | DA | 83 | 83 | NED |
28 | 14 | 1 | Yes | STR | 36; 1.8 | BR (PPF)/SP | Yes | Metastatic | 2 | 8 | DOD |
29 | 35 | 27 | No | NS | 45/36; 1.8 | BR/SP | Yes | Infield | 40 | 99 | DOD |
30 | 16 | 4 | Yes | STR | 30/36 + 18; 1.8 | BR(PPF)/SP(B C) | No | DA | 11 | 11 | NED |
31 | 27 | 2 | No | NS | 40; 1.8 | BR/SP to L1 | No | DA | 69 | 69 | NED |
32 | 17 | 2 | Yes | STR | 36 + 9; 1.8 | BR (PPF)/SP(B C) | Yes | Metastatic | 6 | 8 | DOD |